Iloprost is a prostacyclin (PGI2) analog that affects platelet aggregation[1]. Clinically, Iloprost is used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon, frostbite, and other conditions characterized by impaired blood flow to tissues due to vasoconstriction[2, 3].
In vitro, pretreatment of pulmonary endothelial cells with Iloprost (200ng/mL) for 15min significantly reduced the permeability of FITC-labeled dextran induced by lipopolysaccharide (LPS), mitigating LPS-induced disruption of the endothelial cell monolayer[4]. Treatment of human periodontal ligament cells (hPDLs) with Iloprost (1μM) for 24h promoted the mRNA and protein expression of VEGF and COL1 in the cells[5].
In vivo, oral administration of Iloprost (1, 4, and 10μg/kg) to mice in a mesenteric artery thrombosis model reduced thrombosis in the mesenteric arterioles in a dose-dependent manner[6].
References:
[1] Kobzar G, Mardla V, Järving I, et al. Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets[J]. Cellular Physiology and Biochemistry, 2001, 11(5): 279-284.
[2] Foti R. Treatment with intravenous iloprost in patients with systemic sclerosis: A short review[J]. Journal of Rare Diseases Research & Treatment, 2017, 2(4).
[3] Ruiz J, Watford M, Samuel E, et al. Corticotrophins, corticosteroids, and prostaglandins[M]//Side Effects of Drugs Annual. Elsevier, 2020, 42: 407-415.
[4] Birukova A A, Wu T, Tian Y, et al. Iloprost improves endothelial barrier function in lipopolysaccharide-induced lung injury[J]. European Respiratory Journal, 2012, 41(1): 165-176.
[5] Jearanaiphaisarn T, Sanharati T, Pavasant P, et al. The effect of iloprost on cell proliferation and angiogenesis-related gene expression in human periodontal ligament cells[J]. Odontology, 2018, 106(1): 11-18.
[6] Wang X, Chen S, Wan J, et al. Iloprost Concentration‐Dependently Attenuates Platelet Function and Apoptosis by Elevating PKA Activity[J]. Journal of Cellular and Molecular Medicine, 2025, 29(3): e70403.
Iloprost是一种前列环素（PGI2）类似物，能够影响血小板聚集[1]。Iloprostzai在临床上用于治疗肺动脉高压（PAH）、硬皮病、雷诺现象、冻伤以及其他血管收缩导致血液无法流向组织的疾病[2, 3]。
在体外，Iloprost（200ng/mL）预处理肺内皮细胞15min，显著降低了脂多糖（LPS）诱导的FITC标记葡聚糖的透过率，减轻了脂多糖诱导的内皮细胞单层破坏[4]。Iloprost（1μM）处理人牙周膜细胞（hPDLs）24h，促进了细胞中VEGF 和COL1的mRNA和蛋白表达[5]。
在体内，Iloprost（1, 4 and 10μg/kg）通过口服治疗肠系膜动脉血栓形成模型小鼠，以剂量依赖性方式减轻了小鼠肠系膜小动脉中的血栓形成[6]。